Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2002-07-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-002-0484-9PMID 12203099
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms of drug resistance in ovarian cancer

  2010influential reference
• A Literature Review

  2006cited by this paper
• Pharmacokinetic and Pharmacodynamic Considerations

  2006cited by this paper
• Multidrug resistance in cancer chemotherapy

  2004cited by this paper
• Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein

  2004cited by this paper
• Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate

  2004cited by this paper
• A Phase I study of infusional vinblastine in combination with the p‐glycoprotein antagonist PSC 833 (valspodar)

  2001cited by this paper
• Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.

  2001cited by this paper
• Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies.

  2000cited by this paper
• Phase I trial of paclitaxel plus megestrol acetate in patients with paclitaxel-refractory ovarian cancer.

  2000cited by this paper
• Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR-mediated retinal and macular degeneration.

  2000cited by this paper
• ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport.

  2000cited by this paper
• Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux.

  1999cited by this paper
• Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred.

  1999cited by this paper
• Megestrol acetate therapy and secondary adrenal suppression

  1999cited by this paper
• Corticosteroid Effects of Megestrol Acetate

  1998cited by this paper
• Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.

  1997cited by this paper
• Augmentation of vincristine cytotoxicity by megestrol acetate

  1997cited by this paper
• Sensitization to doxorubicin resistance in breast cancer cell lines by tamoxifen and megestrol acetate.

  1996cited by this paper
• Megestrol acetate in patients with AIDS-related cachexia.

  1996cited by this paper
• P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal.

  1996cited by this paper
• Megestrol Acetate in Patients with AIDS and Cachexia

  1994cited by this paper
• Megestrol acetate in patients with AIDS-related cachexia.

  1994cited by this paper
• Rapid and sensitive high-performance liquid chromatographic assay for novobiocin in human serum.

  1994cited by this paper
• Phase III evaluation of 4 doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia.

  1994cited by this paper
• Clinical trials of agents that reverse multidrug resistance. A literature review

  1993cited by this paper
• Biochemistry of multidrug resistance mediated by the multidrug transporter.

  1993cited by this paper
• Reversal of multidrug resistance to cancer chemotherapy

  1993cited by this paper
• ABC transporters: from microorganisms to man.

  1992cited by this paper
• Multidrug resistance in human cancer.

  1992influential reference
• High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine.

  1992cited by this paper
• Phase I and pharmacokinetic study of D-verapamil and doxorubicin.

  1991cited by this paper
• Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia.

  1990cited by this paper
• Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus.

  1989cited by this paper
• Steroid hormones inhibit binding of Vinca alkaloid to multidrug resistance related P-glycoprotein.

  1989cited by this paper
• High-dose megestrol acetate in the treatment of advanced breast cancer.

  1988cited by this paper
• High-dose megestrol acetate. A possible treatment for cachexia.

  1986cited by this paper
• High-dose megestrol acetate in the treatment of postmenopausal women with advanced breast cancer.

  1986cited by this paper

• Enhanced oral bioavailability of megestrol acetate via polymer-hybridized solid lipid nanoparticles using ultrasonic nebulization method

  2024cites this paper
• Antitumor progestins activity: Cytostatic effect and immune response.

  2024cites this paper
• Progestins as Anticancer Drugs and Chemosensitizers, New Targets and Applications

  2021cites this paper
• Megestrol acetate is a specific inducer of CYP3A4 mediated by human pregnane X receptor

  2021cites this paper
• Metabolism of megestrol acetate in vitro and the role of oxidative metabolites

  2018cites this paper
• Metastasis and drug resistance

  2009cites this paper
• Drugs and HPA axis

  2008cites this paper
• Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial.

  2007cites this paper
• In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity at CYP-450.

  2006cites this paper
• In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).

  2006cites this paper
• Drug-Metabolizing Enzymes and P-Glycoprotein

  2004cites this paper